Cell survival and apoptosis-related molecules in cancer cells in effusions: A comprehensive review

Diagnostic Cytopathology

Volumn 37, Issue 8, 2009, Pages 613-624

  Kleinberg, Lilach ^a   Davidson, Ben ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Apoptosis; Cell survival; Effusions

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; DEATH RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; PROCASPASE 9; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE A; SURVIVIN; TRANSCRIPTION FACTOR NF E2; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER SURVIVAL; CELL SURVIVAL; CLINICAL FEATURE; EFFUSION; FLOW CYTOMETRY; GENE DELETION; GENE MUTATION; HUMAN; KNOWLEDGE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; NICK END LABELING; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TUMOR GROWTH;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BODY FLUIDS; CELL SURVIVAL; HUMANS; NEOPLASMS; NF-KAPPA B;

EID: 67650996296     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21095     Document Type: Article

References (173)

1. Davidson B. Biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog 2007;13:189-227. (Pubitemid 351239093)
2. Nagy JA, Masse EM, Herzberg KT, et al. Pathogenesis of ascites tumor growth: Vascular permeability factor, vascular hyperpermeability, and ascites tumor accumulation. Cancer Res 1995;55:360-368.
3. Hirabayashi K, Graham J. The genesis of ascites in ovarian cancer. Am J Obstet Gynecol 1970;106:492-497.
4. Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 2008;1785:232-265.
5. Artega CL. Inhibiting tyrosine kinases. Cancer Biol Ther 2 (4 Suppl 1): 2003;S79-S83.
6. Di Carlo A, Mariano A, Terracciano D, et al. Gelatinolytic activities (matrix metalloproteinase-2 and -9) and soluble extracellular domain of Her-2/neu in pleural effusions. Oncol Rep 2007;18: 425-431.
7. Hung TL, Chen FF, Liu JM, et al. Clinical evaluation of HER-2/ neu protein in malignant pleural effusion-associated lung adenocarcinoma and as a tumor marker in pleural effusion diagnosis. Clin Cancer Res 2003;9:2605-2612. (Pubitemid 36842103)
8. Porcel JM, Salud A, Vives M, Esquerda A, Rodríguez-Panadero F. Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions. Clin Biochem 2005;38:1031-1033. (Pubitemid 41606801)
9. Harlozińska A, Bar JK, Sobańska E, Goluda M. Epidermal growth factor receptor and c-erbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms. Tumour Biol 1998;19:364-373. (Pubitemid 28384462)
10. Shih JY, Gow CH, Yu CJ, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006;118:963-969. (Pubitemid 43157672)
11. Soh J, Toyooka S, Aoe K, et al. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer 2006;119:2353-2358. (Pubitemid 44546955)
12. Wu SG, Gow CH, Yu CJ, et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J 2008;32:924-930.
13. Zhang X, Zhao Y, Wang M, Yap WS, Chang AY. Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer. Lung Cancer 2008;60:175-182. (Pubitemid 351609150)
14. Davidson B, Vintman L, Zcharia E, et al. Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. Clin Exp Metastasis 2004;21:469-476.
15. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-475. (Pubitemid 32266815)
16. Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999;54:707-710. (Pubitemid 29341408)
17. Langerak AW, De Laat PA, Van Der Linden-Van Beurden CA, et al. Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J Pathol 1996;178:151-160. (Pubitemid 26057966)
18. Economidou F, Antoniou KM, Tzanakis N, Sfiridaki K, Siafakas NM, Schiza SE. Angiogenic molecule Tie-2 and VEGF in the pathogenesis of pleural effusions. Respir Med 2008;102:774-779.
19. Davidson B, Lazarovici P, Ezersky A, et al. Expression levels of the NGF receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Clin Cancer Res 2001;7:3457-3464. (Pubitemid 33069981)
20. Davidson B, Reich R, Lazarovici P, et al. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res 2003;9:2248-2259. (Pubitemid 36687650)
21. Davidson B, Reich R, Lazarovici P, Flørenes VA, Nielsen S, Nesland JM. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provides the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat 2004;83:119-128. (Pubitemid 38161258)
22. Davidson B, Reich R, Lazarovici P, et al. Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer 2004;44:159-165. 23. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21: 485-495. (Pubitemid 38482048)
23. Taylor RC, Cullen SP, Martin SJ. Apoptosis: Controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008;9:231-241. (Pubitemid 351301823)
24. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002;2:277-288. (Pubitemid 37328781)
25. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001;15:2922-2933.
26. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004;23:2797-2808.
27. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: The calcium apoptosis link. Nat Rev Mol Cell Biol 2003;4:552-565. (Pubitemid 36773407)
28. Guicciardi ME, Leist M, Gores GJ. Lysosomes in cell death. Oncogene 2004;23:2881-2890.
29. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002;108:153-164. (Pubitemid 34161136)
30. Maddika S, Ande SR, Panigrahi S, et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 2007;10:13-29. (Pubitemid 46636381)
31. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004;5:897-907. (Pubitemid 39486541)
32. Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984;226:1097-1099. (Pubitemid 15217831)
33. Strasser A, Harris AW, Bath ML, et al. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990;348:331-333. (Pubitemid 120029100)
34. Jäger R, Herzer U, Schenkel J, et al. Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice. Oncogene 1997;15:1787-1795. (Pubitemid 27478621)
35. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91. (Pubitemid 26008141)
36. Liu JR, Opipari AW, Tan L, et al. Dysfunctional apoptosome activation in ovarian cancer: Implications for chemoresistance. Cancer Res 2002;62:924-931. (Pubitemid 34126974)
37. Abedini MR, Qiu Q, Yan X, et al. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 2004;23:6997-7004. (Pubitemid 39319162)
38. Yang X, Zheng F, Xing H, et al. Resistance to chemotherapyinduced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J Cancer Res Clin Oncol 2004;130:423-428. (Pubitemid 39044346)
39. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-257.
40. Watanabe M, Hitomi M, van der Wee K, et al. The pros and cons of apoptosis assays for use in the study of cells, tissues, and organs. Microsc Microanal 2002;8:375-391. (Pubitemid 35456712)
41. Vermes I, Haanen C, Reutelingsperger C. Flow cytometry of apoptotic cell death. J Immunol Methods 2000;243:167-190. (Pubitemid 30734601)
42. Otsuki Y, Li Z, Shibata MA. Apoptotic detection methods-from morphology to gene. Prog Histochem Cytochem 2003;38:275-339. (Pubitemid 36538343)
43. Kaufmann SH, Lee SH, Meng XW, et al. Apoptosis-associated caspase activation assays. Methods 2008;44:262-272.
44. Darzynkiewicz Z, Juan G, Li X, et al. Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis). Cytometry 1997;27:1-20. (Pubitemid 27059777)
45. Darzynkiewicz Z, Bedner E, Traganos F. Difficulties and pitfalls in analysis of apoptosis. Methods Cell Biol 2001;63:527-546.
46. Belloc F, Belaud-Rotureau MA, Lavignolle V, et al. Flow cytometry detection of caspase 3 activation in preapoptotic leukemic cells. Cytometry 2000;40:151-160. (Pubitemid 30322378)
47. Schmid I, Uittenbogaart C, Jamieson BD. Live-cell assay for detection of apoptosis by dual-laser flow cytometry using Hoechst 33342 and 7-amino-actinomycin D. Nat Protoc 2007;2:187-190. (Pubitemid 47040082)
48. Troiano L, Ferraresi R, Lugli E, et al. Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry. Nat Protoc 2007;2:2719-2727.
49. Komoriya A, Packard BZ, Brown MJ, et al. Assessment of caspase activities in intact apoptotic thymocytes using cell-permeable fluorogenic caspase substrates. J Exp Med 2000;191:1819-1828. (Pubitemid 30390346)
50. Bedner E, Smolewski P, Amstad P, et al. Activation of caspases measured in situ by binding of fluorochrome-labeled inhibitors of caspases (FLICA): Correlation with DNA fragmentation. Exp Cell Res 2000;259:308-313. (Pubitemid 30681536)
51. Pozarowski P, Huang X, Halicka DH, et al. Interactions of fluorochrome-labeled caspase inhibitors with apoptotic cells: A caution in data interpretation. Cytometry A 2003;55:50-60. (Pubitemid 37522521)
52. Arends MJ, Morris RG, Wyllie AH. Apoptosis the role of the endonuclease. Am J Pathol 1990;136:593-608.
53. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
54. Gorczyca W, Bigman K, Mittelman A, et al. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia 1993;7:659-670. (Pubitemid 23186018)
55. Gorczyca W, Bruno S, Darzynkiewicz R, et al. DNA strand breaks occurring during apoptosis: Their early in situ detection by the terminal deoxynucleotidyl transferase and nick translation assays and prevention by serine protease inhibitors. Int J Oncol 1992;1:639-648.
56. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, et al. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 1995;21:1465-1468.
57. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980;284: 555-556. (Pubitemid 10070336)
58. Oberhammer F, Wilson JW, Dive C, et al. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 1993;12:3679-3684. (Pubitemid 23256455)
59. Ormerod MG, O'Neill CF, Robertson D, et al. Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exp Cell Res 1994; 211:231-237. (Pubitemid 24174952)
60. Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995;182:1545-1556.
61. van Engeland M, Nieland LJ, Ramaekers FC, et al. Annexin Vaffinity assay: A review on an apoptosis detection system based on phosphatydilserine exposure. Cytometry 1998;31:1-9. (Pubitemid 28050057)
62. Andree HA, Reutelingsperger CP, Hauptmann R, et al. Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. J Biol Chem 1990;265:4923-4928. (Pubitemid 20117129)
63. Koopman G, Reutingsperger CP, Kuijten GA, et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994;84:1415-1420. (Pubitemid 24273007)
64. van Engeland M, Ramaekers FC, Schutte B, et al. A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 1996;24:131-139. (Pubitemid 26202924)
65. Pozarowski P, Grabarek J, Darzynkiewicz Z. Flow cytometry of apoptosis. Curr Protoc Cell Biol 2004;Chapter 18:Unit 18.8.
66. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281:1309-1312.
67. Marchetti P, Castedo M, Susin SA, et al. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 1996;184:1155-1560. (Pubitemid 26313572)
68. Finucane DM, Waterhouse NJ, Amarante-Mendes GP, et al. Collapse of the inner mitochondrial transmembrane potential is not required for apoptosis of HL60 cells. Exp Cell Res 1999;251:166-174. (Pubitemid 29406530)
69. Matsuzaki Y, Edagawa M, Shimizu T, et al. Intrapleural hyperthermic perfusion with chemotherapy increases apoptosis in malignant pleuritis. Ann Thorac Surg 2004;78:1769-1772. (Pubitemid 39423551)
70. Sikora J, Dworacki G, Zeromski J. Expression of Fas and Fas ligand and apoptosis in tumor-associated lymphocytes and in tumor cells from malignant pleural effusions. Nat Immun 1998; 16:244-255. (Pubitemid 30764961)
71. Dong HP, Kleinberg L, Davidson B, Risberg B. Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry. Nat Protoc 2008; 3:955-964. (Pubitemid 351818684)
72. Kleinberg L, Dong HP, Holth A, et al. Cleaved caspases and NF-κB are prognostic factors in metastatic ovarian carcinoma. Hum Pathol 2009 Jan 19 [Epub ahead of print].
73. Schimmer AD. Inhibitor of apoptosis proteins: Translating basic knowledge into clinical practice. Cancer Res 2004;64:7183-7190. (Pubitemid 39372048)
74. Liston P, Fong WG, Korneluk RG. The inhibitors of apoptosis: There is more to life than Bcl2. Oncogene 2003;22:8568-8580. (Pubitemid 38019194)
75. Sun C, Cai M, Gunasekera AH, et al. NMR structure and mutagenesis of the inhibitor-of -apoptosis protein XIAP. Nature 1999; 401:818-822. (Pubitemid 129515846)
76. Shiozaki EN, Chai J, Rigotti DJ, et al. Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell 2003;11:519-527.
77. Roy N, Deveraux QL, Takahashi R, et al. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997; 16:6914-6925. (Pubitemid 27520792)
78. Takahashi R, Deveraux Q, Tamm I, et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem 1998;273: 7787-7790. (Pubitemid 28168819)
79. Maier JK, Lahoua Z, Gendron NH, et al. The neuronal apoptosis inhibitory protein is a direct inhibitor of caspase 3 and 7. J Neurosci 2002;22:2035-2043. (Pubitemid 35386504)
80. Sanna MG, da Silva Correia J, Ducrey O, et al. IAP suppression of apoptosis involves distinct mechanisms: The TAK1/JNK1 signaling cascade and caspase inhibition. Mol Cell Biol 2002;22: 1754-1766.
81. Chu ZL, Mckinsey TA, Liu L, et al. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA 1997;94:10057-10062. (Pubitemid 27406993)
82. Hofer-Warbinke R, Schmid JA, Stehlik C, et al. Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J Biol Chem 2000;275: 22064-22068. (Pubitemid 30621784)
83. Levkau B, Garton KJ, Ferri N, et al. XIAP induces cell-cycle arrest and activates nuclear factor-kappaB: New survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ Res 2001;88:282-290. (Pubitemid 32173751)
84. Li F, Ambrosini G, Chu EY et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-584. (Pubitemid 28563719)
85. Altieri DC. Survivin, versatile modulation of cell division and spoptosis in cancer. Oncogene 2003;22:8581-8589. (Pubitemid 38019195)
86. Fortugno P, Wall NR, Giodini A, et al. Survivin exists in immuno-histochemically distinct subcellular pools and involved in spindle microtubule function. J Cell Sci 2002;115:575-585. (Pubitemid 34182984)
87. O'Connor D, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000;97:13103-13107.
88. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000;6:1796-1803. (Pubitemid 30305074)
89. Nachmias B, Ashhab Y, Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): An emerging therapeutic target in cancer. Semin Cancer Biol 2004;14:231-243. (Pubitemid 38824584)
90. Li J, Feng Q, Kim JM, et al. Human ovarian cancer and cisplatin resistance: Possible role of inhibitor of apoptosis proteins. Endocrinology 2001;142:370-380. (Pubitemid 32183698)
91. Wu M, Yuan S, Szporn AH, et al. Immunohistochemical detection of XIAP in body cavity effusions and washes. Mod Pathol 2005; 18:1618-1622. (Pubitemid 41670662)
92. Kleinberg L, Flørenes VA, Silins I, et al. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer 2007;109:228-238. (Pubitemid 46106237)
93. Kleinberg L, Flørenes VA, Nesland JM, Davidson B. Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions. Am J Clin Pathol 2007;128:389-397. (Pubitemid 47479971)
94. Kleinberg L, Lie AK, Flørenes VA, et al. Expression of inhibitorof- apoptosis protein family members in malignant mesothelioma. Hum Pathol 2007;38:986-994. (Pubitemid 46899149)
95. Wu M, Sun Y, Li G, et al. Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions. Am J Clin Pathol 2007;128:783-787. (Pubitemid 350133989)
96. Ashkenazi A. Targeting death and decoy receptors of the tumornecrosis factor superfamily. Nat Rev Cancer 2002;2:420-430. (Pubitemid 37328939)
97. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65.
98. Takeda K, Stagg J, Yagita H, et al. Targeting death-inducing receptors in cancer therapy. Oncogene 2007;26:3745-3757. (Pubitemid 46842709)
99. Özören N, El-Deiry WS. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 2003;13:135-147. (Pubitemid 36321814)
100. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228-237. (Pubitemid 40315182)
101. Müschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med 2000;78:312-325. (Pubitemid 30672254)
102. Rippo MR, Moretti S, Vescovi S. FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 2004;23:7753-7760. (Pubitemid 39457025)
103. Scaffidi C, Fulda S, Srinivasan A. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675-1687. (Pubitemid 28119121)
104. Desbarats J, Birge RB, Mimouni-Rongy M, et al. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 2003;5:118-125. (Pubitemid 36204194)
105. Shinohara H, Yagita H, Ikawa Y, et al. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res 2000;60:1766-1772. (Pubitemid 30183454)
106. Secchiero P, Gonelli A, Carnevale E, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003; 107:2250-2256. (Pubitemid 36547221)
107. Morel J, Audo R, Hahne M, et al. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen- activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005; 280:15709-15718. (Pubitemid 40616690)
108. Imamura R, Konaka K, Matsumoto N, et al. Fas ligand induces cell-autonomous NF-kB activation and interleukin-8 production by a mechanism distinct from that of tumor necrosis factor-α. J Biol Chem 2004;279:46415-46423. 110. Leverkus M, Sprick MR, Wachter T, et al. TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: Differential contribution of TRAIL receptors 1 and 2. J Invest Dermatol 2003;121: 149-155. (Pubitemid 39518283)
109. Reichmann E. The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol 2002;12: 309-315. (Pubitemid 35034575)
110. Barnhart BC, Legembre P, Pietras E, et al. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 2004;23:3175-3185. (Pubitemid 39093611)
111. Lee JK, Sayers TJ, Back TC, et al. Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer. Apoptosis 2003;8:151-160. (Pubitemid 36547102)
112. Liu ZG, Hsu H, Goeddel DV, et al. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996;87:565-576. (Pubitemid 26374329)
113. Balkwill F. TNF-α in promotion and progression of cancer. Cancer Met Rev 2006;25:409-416.
114. Dempsey PW, Doyle SE, He JQ, et al. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003;14:193-209. (Pubitemid 36693141)
115. Lane D, Robert V, Grondin R, et al. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer 2007; 121:1227-1237. (Pubitemid 47293789)
116. Wu S, Boyer CM, Whitaker RS, et al. Tumor necrosis factor α as an autocrine and paracrine growth factor for ovarian cancer: Monokine induction of tumor cell proliferation and tumor necrosis factor α expression. Cancer Res 1993;53:1939-1944. (Pubitemid 23127128)
117. Mitani K, Nishioka Y, Yamabe K, et al. Soluble Fas in malignant pleural effusion and its expression in lung cancer. Cancer Sci 2003;94:302-307. (Pubitemid 36575899)
118. Wang PS, Chen YM, Hsieh YL, Yu CF, Tsai CM, Perng RP. Pleural effusion and serum soluble fas-ligand levels are elevated in different clinical conditions. Lung 2002;180:25-32. (Pubitemid 36002436)
119. Dong HP, Kleinberg L, Silins I, et al. Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer 2008;112:84-93.
120. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007;8:49-62. (Pubitemid 46012014)
121. Neumann M, Naumann M. Beyond IkappaBs: Alternative regulation of NF-kappaB activity. FASEB J 2007;21:2642-2654.
122. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853-6866.
123. Perkins ND, Gilmore TD. Good cop, bad cop: The different faces of NF-kappaB. Cell Death Differ 2006;13:759-772.
124. Perkins ND. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 2006;25:6717-6730. (Pubitemid 44657848)
125. Viatour P, Merville MP, Bours V, et al. Phosphorylation of NF-kappaB and IkappaB proteins: Implications in cancer and inflammation. Trends Biochem Sci 2005;30:43-52. (Pubitemid 40093740)
126. Sakurai H, Chiba H, Miyoshi H, et al. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 1999;74:30353-30356. (Pubitemid 129576764)
127. Sizemore N, Lerner N, Dombrowski N, et al. Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem 2002;277:3863-3869. (Pubitemid 34968637)
128. Bohuslav J, Chen LF, Kwon H, et al. p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem 2004;279:26115-26125. (Pubitemid 38798756)
129. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kappaB activation: From bench to bedside. Exp Biol Med (Maywood) 2008;233:21-31.
130. Bassères DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006;25:6817-6830.
131. Pianetti S, Arsura M, Romieu-Mourez R, et al. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 2001;20: 1287-1299. (Pubitemid 32269934)
132. Finco TS, Westwick JK, Norris JL, et al. Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem 1997;272:24113-24116. (Pubitemid 27418602)
133. Reuther JY, Reuther GW, Cortez D, et al. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 1998;12:968-981. (Pubitemid 28204604)
134. Zhou H, Du MQ, Dixit VM. Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 2005;7:425-431. (Pubitemid 40719126)
135. Ikenoue T, Hikiba Y, Kanai F, et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 2003;63:8132-8137. (Pubitemid 37549459)
136. Madrid LV, Wang CY, Guttridge DC, et al. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol 2000;20:1626-1638. (Pubitemid 30100182)
137. Madrid LV, Mayo MW, Reuther JY, et al. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 2001;276: 18934-18940. (Pubitemid 37411214)
138. Xiao CW, Yan X, Li Y, et al. Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domainlike interleukin-1beta-converting enzyme-like inhibitory protein. Endocrinology 2003;144:623-630. (Pubitemid 36205236)
139. Tang G, Minemoto Y, Dibling B, et al. Inhibition of JNK activation through NF-kappaB target genes Nature 2001;14:313-317.
140. Chen C, Edelstein LC, Gélinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000;20:2687-2695.
141. Wang CY, Guttridge DC, Mayo MW, et al. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999;19: 5923-5929. (Pubitemid 29399297)
142. Chen X, Kandasamy K, Srivastava RK. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 2003;63:1059-1066. (Pubitemid 36278439)
143. Izzo JG, Malhotra U, Wu TT, et al. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006;24:748-754. (Pubitemid 46622041)
144. Izzo JG, Malhotra U, Wu TT, et al. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev 2007;16: 1200-1205. (Pubitemid 46984959)
145. Montagut C, Tusquets I, Ferrer B, et al. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer 2006;13:607-616. (Pubitemid 43886680)
146. Weichert W, Boehm M, Gekeler V, et al. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer 2007;97:523-530. (Pubitemid 47258447)
147. Zhang D, Jin X, Wang F, et al. Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer. Ann Surg Oncol 2007;14:3581-3592. (Pubitemid 350160125)
148. Liu GH, Wang SR, Wang B, et al. Inhibition of nuclear factor-kappaB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line. Int J Gynecol Cancer 2006;16:1777-1782. (Pubitemid 44470035)
149. Mabuchi S, Ohmichi M, Nishio Y, et al. Inhibition of NF-kappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 2004;279:23477-23485. (Pubitemid 38685659)
150. Mabuchi S, Ohmichi M, Nishio Y, et al. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res 2004;10:7645-7654. (Pubitemid 39557528)
151. Schimmer AD, Dalili S, Batey RA, et al. Targeting XIAP for the treatment of malignancy. Cell Death Differ 2006;13:179-188.
152. LaCasse EC, Kandimalla ER, Winocour P, et al. Application of XIAP antisense to cancer and other proliferative disorders: Development of AEG35156/ GEM640. Ann N Y Acad Sci 2005;1058: 215-234.
153. LaCasse EC, Cherton-Horvat GG, Hewitt KE, et al. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res 2006;12:5231-5241. (Pubitemid 44453353)
154. Arnt CR, Chiorean MV, Heldebrant MP, et al. Synthetic Smac/ DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 2002;277: 44236-44243. (Pubitemid 36157856)
155. Schimmer AD, Welsh K, Pinilla C, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004;5:25-35. (Pubitemid 38121594)
156. Yang L, Mashima T, Sato S, et al. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: Therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res 2003;63:831-837. (Pubitemid 36231984)
157. Oost TK, Sun C, Armstrong RC, et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 2004;47:4417-4426. (Pubitemid 39096830)
158. Petrucci E, Pasquini L, Petronelli A, et al. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol Oncol 2007;105:481-492. (Pubitemid 46590342)
159. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: Fulfilled promises and open questions. Carcinogenesis 2007;28:1133-1139. (Pubitemid 47062670)
160. Tolcher AW, Antonia S, Lewis LD, et al. A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors (ASCO Annual Meeting Proceedings). J Clin Oncol 2006;24:3014.
161. Tsuruma T, Hata F, Torigoe T, et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004;2:19. (Pubitemid 39130353)
162. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004;4:333-339. (Pubitemid 38987058)
163. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist 2006;11:397-408.
164. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162.
165. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163. (Pubitemid 29068521)
166. Pukac L, Kanakaraj P, Humphreys R, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005; 92:1430-1441. (Pubitemid 40705010)
167. Belyanskaya LL, Marti TM, Hopkins-Donaldson S, et al. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer 2007;6:66. (Pubitemid 350278695)
168. Marini P, Denzinger S, Schiller D, et al. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: Enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006;25:5145-5154. (Pubitemid 44285983)
169. Tolcher AW, Mita M, Meropol NJ, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007; 25:1390-1395. (Pubitemid 46706887)
170. Hotte SJ, Hirte HW, Chen EX, et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008; 14:3450-3455.
171. Plummer R, Attard G, Pacey S, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007;13:6187-6194. (Pubitemid 350075080)
172. Greco FA, Bonomi P, Crawford J, et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008;61:82-90.
173. Bunkholt Elstrand M, Kleinberg L, Kohn EC, Tropé CG, Davidson B. Expression and clinical role of anti-apoptotic proteins of the Bag, Heat Shock and Bcl-2 families in effusions, primary tumors and solid metastases in ovarian carcinoma. Int J Gynecol Pathol, in press.